Share Print

January 2012 Funding Opportunities

SPOTLIGHTED FUNDING OPPORTUNITY

Alvin J. Siteman Cancer Research Fund (for exceptionally innovative scientific investigations)
This is an internal competition for Washington University faculty.  The fund is targeted specifically for innovative programs that epitomize scientific ingenuity, but might not receive funding from federal agencies.  Funding is focused exclusively on exceptionally innovative projects with the potential for transformative impact.

Preproposals due January 3, 2012.  If invited, full proposals due April 30, 2012.
http://internalcompetitions.wustl.edu/ocfr/grants.nsf/d20d347a226ec79c862567ad005a8e33/c6da0a0aaed31ae3862577a40050d076?OpenDocument

FOUNDATION OPPORTUNITIES

LUNGevity Foundation invites applications for its first Career Development Awards for Translational Research. Research projects restricted to translational lung cancer research. Applicant must demonstrate the translational relevance of the research proposed. Proposed projects must make use of human biopsies or samples. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not.  Translational research includes epidemiology studies, and the foundation especially encourages clinical correlative studies. Applicants must be junior faculty members who are within the first five years of their faculty appointment (at the start of the grant term) and have not won a major award. Applicants must be employed by a US institution.

$100,000 (direct and indirect) per year, up to three years.
LOI deadline:   December 30, 2011
Application deadline:  March 19, 2012
http://events.lungevity.org/site/PageServer?pagename=v2_Research_ApplicationDetails

The National Comprehensive Cancer Network (NCCN) has funding for NCCN investigator-initiated clinical studies that focus on developing innovative studies to help determine the role of afatinib in the treatment of specific solid tumors. The funding is derived from a research agreement and collaboration between NCCN and Boehringer Ingelheim.
Application deadline: January 9, 2012
http://www.nccn.org/clinical_trials/investigators/default.asp

AACI Translational Cancer Research Fellowship (Limited competition)
The intent of the fellowship is to provide additional support to individuals who are engaged in any area of clinical and/or translational cancer research in order to further the development of their careers and enhance their future success in an academic discipline. The AACI fellowship will provide a one-year $50,000 non-renewable grant to support post-doctoral training to individuals who have completed at least one year of training in any field of oncology and have at least one year of training remaining at an AACI member institution.
http://www.aaci-cancer.org/fellowship.asp
Application deadline:  February 1, 2012, at 12:00 noon, EST
 

Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research.
Award will support highly meritorious research that is being conducted collaboratively by investigators in different countries around the world. The goals of the program are to overcome barriers to international collaboration by providing funding for costs traditional grant mechanisms may not support; raise the profile of the importance of collaboration to conquering the cancer problem; and provide the means to facilitate travel and the sharing of knowledge that otherwise may have been difficult to achieve.

Applications accepted from two or more independent investigators working within an established international cancer research collaboration involving institutes in multiple countries. Proposals to initiate a collaborative project will not be accepted. Only one investigator per institution is to be identified as a Collaborator.

$50,000 per year for two years.
Application deadline:  January 18, 2012
http://www.aacr.org/home/scientists/aacr-research-funding/current-funding-opportunities-for-independent-researchers.aspx#lanInt

Landon Foundation-AACR INNOVATOR Award for Research in Personalized Cancer Medicine. The use of genomics to accurately predict individual responses to treatment with a drug or biologic agent is a central component of the future of personalized cancer medicine.  There is a growing need not only to be able to predict which patients will respond to a particular treatment, but also who are likely to be the non-responders.  to accelerate progress in this area by providing support for physician-scientists who conduct meritorious studies with direct human therapeutic relevance.
Applicant must be MD or MD/PhD and hold a faculty position for no more than 10 years.

$50,000 per year for two years.
Application deadline:  January 18, 2012
http://www.aacr.org/home/scientists/aacr-research-funding/current-funding-opportunities-for-independent-researchers.aspx#lanInt

AACR  Current Junior Faculty Funding Opportunities:

  • AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway; $50,000/yr for 2 years; Application deadline: January 10, 2012
  • AACR Judah Folkman Career Development Award for Antiangiogenesis Research; $50,000/yr for 2 years; Application deadline: January 10, 2012.
  • Fight Colorectal Cancer-AACR Career Development Award, in memory of Lisa Dubow; $50,000/yr for 2 years; Application deadline: January 17, 2012
  • Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research; $50,000/yr for 2 years; Application deadline: January 18, 2012
    http://www.aacr.org/home/scientists/aacr-research-funding/current-funding-opportunities-for-junior-faculty.aspx#FCC 

Sarcoma Foundation of America makes funds available in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human Sarcomas. In accordance with the mission of the Foundation, research involving the development of novel agents against Sarcoma, or research that could potentially lead to the development of novel agents against Sarcoma, is eligible for this funding. Preference will be given to proposals on promising molecular targets and new or uncommon therapeutic approaches.
$50,000 for one year.

Application deadline:  January 31, 2012
http://www.curesarcoma.org/index.php/research_grants/grant_applications

NIH & NCI  OPPORTUNITIES

Announcements

The National Cancer Institute is participating in an NIH initiative to enhance ongoing research efforts through collaborations with Chinese scientists under the new U.S.-China Program for Biomedical Research Cooperation. This Administrative Supplement opportunity is available only to active research projects that are supported by specified NIH funding mechanisms. All the requests for supplemental funding must be based on collaborations involving eligible awardees and qualifying Chinese investigators. Additional specific requirements and eligibility conditions apply (see full details at http://grants.nih.gov/grants/guide/notice-files/NOT-CA-12-002.html). Receipt date is February 21, 2012.

Request for Applications

NCI R21 Early-Stage Innovative Technology Development for Cancer Research
(RFA-CA-12-002)  This FOA is intended for exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use.
Application Receipt Date(s): February 23, 2012; May 21, 2012; September 18, 2012

NCI R33 Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)
(RFA-CA-12-003)  This FOA solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system or context.
Application Receipt Date(s): February 23, 2012; May 21, 2012; September 18, 2012

NCI R21 Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)
(RFA-CA-12-004)  This FOA solicits grant applications proposing technically innovative feasibility studies focused on early stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives.
Application Receipt Date(s): February 23, 2012; May 21, 2012; September 18, 2012

NCI R33 Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)
(RFA-CA-12-005)   This FOA solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses.

Application Receipt Date(s): February 23, 2012; May 21, 2012; September 18, 2012

Program Announcements

NCI R01Collaborations with National Centers for Biomedical Computing
(PAR-12-001) Funding available for projects from individual investigators or small groups to collaborate with the NIH Common Fund for Medical Research National Centers for Biomedical Computing (NCBCs). For a description of the NCBCs see http://www.ncbcs.org/. The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones.

Earliest submission date:  January 5, 2012

NCI K05 Established Investigator Award in Cancer Prevention and Control
(PAR-12-065)   The purpose of this award is to provide protected time to senior investigators with exceptional mentoring records and sustained, high levels of research productivity in cancer prevention, cancer control, or the behavioral or population sciences to devote to research and mentoring.

Earliest Application Receipt/Submission Date:  January 12, 2012

NCI K07 Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award
(PAR-12-067)  The purpose of this award is to support the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences.

Earliest Application Receipt/Submission Date:  January 12, 2012

NCI P01 Program Project Application
(PAR-12-005)  Proposed program projects may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer treatment, cancer diagnosis, cancer prevention, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each Program Project application must consist of at least three component projects. The component projects must share a common central theme, focus, and/or overall objective.

Application Receipt/Submission Date(s): Standard Due Dates; January 25, 2012

NCI R01 Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act
(PAR-12-010) This FOA is to support an expansion of the scope of approved and funded R01 projects involving smoking and tobacco-related products and/or their constituents.  This FOA seeks competitive revision projects that address such aspects as: the toxicity and use of new and emerging tobacco products; effective methods to substantially reduce toxicity of tobacco products and smoke; effective methods to substantially reduce the overall addictiveness of cigarettes and other tobacco products; and consumer perceptions and behaviors related to tobacco products, claims, and communications regarding tobacco products.

Letter Of Intent due 01/30/12;  Application Receipt/Submission Date(s): February 17, 2012

NCI R01 Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials.
PA-12-013  The purpose of this FOA is to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker.

Application Receipt/Submission Date: February 5, 2012
http://grants.nih.gov/grants/guide/pa-files/PA-12-013.html

NCI R03 Small Grants for Behavioral Research in Cancer Control
(PAR-12-035)  This FOA is designed to enhance basic and applied behavioral sciences research in the context of cancer control, with a secondary goal of attracting new investigators to the field from a variety of biomedical, behavioral and public health disciplines.

Application Receipt/Submission Date: February 17, 2012